Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver Metastases

Trial Profile

Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver Metastases

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2013

At a glance

  • Drugs Cetuximab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms CELIM
  • Most Recent Events

    • 04 Jun 2013 Overall and progression-free survival results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 21 Jan 2012 Progression-free and overall survival results presented at the 2012 Gastrointestinal Cancers Symposium.
    • 27 Sep 2011 Progression-free survival and overall survival results presented at the 2011 European Multidisciplinary Cancer Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top